Table 4.
Group | TBARS (nmol MDA/mg Prot) | GSH (mg/g Prot) | SOD (U/mg prot) | CAT (U/mg prot) | GSH-Px (U/mg prot) | TAOC (U/mg prot) |
---|---|---|---|---|---|---|
NC | 234.42 ± 0.21 | 23.24 ± 1.33 | 363.14 ± 24.76 | 65.32 ± 0.43 | 52.11 ± 0.34 | 4.74 ± 0.32 |
CCl4-treatment | 8.93 ± 0.65 b | 10.26 ± 1.07 b | 127.39 ± 10.54 b | 32.08 ± 0.14 b | 36.19 ± 0.22 b | 2.13 ± 0.12 b |
CCl4+RPRAE (100 mg/kg b.w.) | 6.85 ± 0.35 d | 16.53 ± 1.25 d | 184.64 ± 13.29 d | 44.08 ± 0.25 d | 42.13 ± 0.27 c | 2.89 ± 0.19 c |
CCl4+RPRAE (200 mg/kg b.w.) | 5.42 ± 0.24 d | 19.62 ± 1.66 d | 295.1 ± 21.64 d | 53.17 ± 0.31 d | 46.27 ± 0.21 d | 3.74 ± 0.14 d |
CCl4+RPRAE (300 mg/kg b.w.) | 4.63 ± 0.3 d | 25.13 ± 1.72 d | 342.72 ± 22.54 d | 62.07 ± 0.36 d | 54.37 ± 0.33 d | 4.83 ± 0.31 d |
CCl4+Bifendate (100 mg/kg b.w.) | 4.98 ± 0.37 d | 26.09 ± 2.01 d | 315.54 ± 25.01 d | 57.53 ± 0.4 d | 50.39 ± 0.38 d | 5.35 ± 0.29 d |
b P < 0.01, compared with NC group; c P < 0.05, d P < 0.01, compared with CCl4-treated group.
Note: NC (normal control).